Cargando…
Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
Probenecid is an orally bioavailable, uricosuric agent that was first approved in 1951 for the treatment of gout, but was later found to have potent, broad-spectrum antiviral activity against several respiratory viruses including SARS-CoV-2. We conducted a phase 2 randomized, placebo-controlled, sin...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386418/ https://www.ncbi.nlm.nih.gov/pubmed/37515194 http://dx.doi.org/10.3390/v15071508 |